CELC · CIK 0001603454
Celcuity Inc.
What Celcuity Inc. owns has not been researched yet. This page is its ownership register, who holds it, and the absence of holdings below means nobody has looked rather than that there is nothing to find.
Celcuity Inc. - Profile
- Industry
- Services-Medical LaboratoriesSIC 8071
- Listed on
- Nasdaq
- Employees
- 155stated 2025
- Incorporated in
- Delaware
- Financial year ends
- 31 December
Source
Address, industry classification, listing and incorporation come from Celcuity Inc.'s own SEC filer record, so the industry is the SEC's dry classification rather than a marketing label. The headcount is the figure the sources below state for 2025. The description was written for this site in August 2026 from Celcuity Inc. Form 10-K for fiscal year 2025, Celcuity Inc. Form 10-Q for the quarter ended 30 June 2026, Celcuity Inc. Form 8-K dated 26 August 2026, Exhibit 99.1 (supplemental NDA submission for REVTORPYK) and Celcuity Inc. Form 8-K dated 13 August 2026, Exhibit 99.1 (second quarter 2026 results), not taken from any single article.
Share price
CELC
Description
Celcuity Inc. is a Minneapolis biotechnology company developing and commercializing targeted therapies for solid tumors. Its only product, REVTORPYK (gedatolisib), is a kinase inhibitor of all four class I PI3K isoforms and both mTOR complexes, blocking the PI3K/AKT/mTOR (PAM) pathway more comprehensively than agents hitting PI3K-alpha, AKT or mTORC1 alone. Rights come from an April 2021 license from Pfizer Inc.: $5.0 million upfront plus 349,406 shares, milestones of up to $335.0 million, and tiered royalties in the low to mid teens. The FDA approved REVTORPYK on 14 July 2026, with fulvestrant, with or without palbociclib, for HR+/HER2- advanced breast cancer without a PIK3CA mutation after at least one line of endocrine therapy, on the Phase 3 VIKTORIA-1 trial, with shipments expected late in the third quarter of 2026. On 26 August 2026 Celcuity filed a supplemental NDA covering the PIK3CA-mutant cohort, where the gedatolisib triplet cut the risk of progression or death by 50% versus alpelisib plus fulvestrant (median PFS 11.1 versus 5.6 months). Phase 3 VIKTORIA-2 tests first-line use and Phase 1b/2 CELC-G-201 pairs gedatolisib with darolutamide in metastatic castration-resistant prostate cancer. Net loss was $177.0 million in 2025 and $131.7 million in the first half of 2026. Cash and short-term investments of $754.0 million at 30 June 2026 are expected to last into 2029.
Who owns Celcuity Inc..
Nothing recorded on this side. That is a sourced finding rather than a gap where the research notes say so: see the notes below.
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 270 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
270 managers reported a position, together holding 49.1m shares, or 100.7% of the company. The 40 largest are listed. Percentages are of the 48.8m shares outstanding at 7 May 2026, the count in force when this quarter was measured rather than the count today.
This adds up to more than the whole company, and that is what the filings say. A 13F total can exceed 100% because the same share can be reported twice: when a holder lends stock, the borrower sells it to someone else, and both the lender's manager and the new buyer's manager report it. The gap tracks how heavily a stock is shorted. It is a property of 13F rather than a fault in this data, so it is shown as filed, and it cannot be used as evidence that a particular holder's stake is large.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Added 27 Aug 2026 by scripts/promote_discovered.py. This company reached the site because a covered investor holds it, not because an index listed it: it was a position in a portfolio here with no page of its own. The match was proved by requiring the register built for this CIK to contain the same CUSIP the portfolio held.
- Discovered at CUSIP 15102K100, held by ameriprise, bank-of-america, blackrock, bny-mellon, citigroup, fidelity-fmr, fifth-third, franklin-resources, geode, goldman-sachs, invesco, jefferies-financial-group, jpmorgan, metlife, morgan-stanley, mt-bank, northern-trust, pfizer, pnc, principal-financial, prudential-financial, raymond-james, state-street, us-bancorp, vanguard, wells-fargo.
- Holdings are NOT researched. The empty holdings list means nobody has looked at what this company owns, not that it owns nothing, and the page says so.
- Shares outstanding and market cap are null rather than guessed. Neither was captured on the dated sweep that carries every other company here.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- Shares outstanding.
- Market capitalisation.